Status:
RECRUITING
Improving Diagnostics in Cervical Dysplasia
Lead Sponsor:
University of Aarhus
Conditions:
Cervical Cancer
Eligibility:
FEMALE
50+ years
Phase:
NA
Brief Summary
Cervical cancer is the fourth most common cancer in women worldwide. It is caused by an infection with human papillomavirus (HPV). A persistent infection with HPV is associated with increased risk of ...
Detailed Description
Cervical cancer is the fourth most common cancer in women worldwide, and comprises approximately 7% of all new cancers in women. To reduce the disease burden, accurate and timely diagnosis of cervical...
Eligibility Criteria
Inclusion
- Postmenopausal (defined as no bleeding ≥1 year) women referred for colposcopy aged ≥ 50 years.
- Women referred for colposcopy due to a positive HPV test and/or an abnormal cervical cytology.
- Women referred for colposcopy due to previous abnormal cervical histology with minimum 6. months since last colposcopy with biopsies.
Exclusion
- Use of estrogen within the last 3 months regardless of administration form.
- previous cervical radiotherapy, cervical amputation and/or cone biopsy
- pregnancy
Key Trial Info
Start Date :
August 23 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 16 2025
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT05283421
Start Date
August 23 2023
End Date
July 16 2025
Last Update
December 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Gynecology and Obstetrics
Randers, Denmark, 8930